{"entity":{"id":"nct04425018","kind":"trial","name":"MARGetuximab Or Trastuzumab (MARGOT)","aka":[],"tldr":"A phase 2 trial of Paclitaxel / nab-paclitaxel, Pertuzumab, Margetuximab, Trastuzumab and Trastuzumab biosimilars in Breast cancer and HER2-positive breast cancer, run by Dana-Farber Cancer Institute, active and no longer recruiting.","summary":"MARGetuximab Or Trastuzumab (MARGOT) is a phase 2 interventional study registered as NCT04425018 by Dana-Farber Cancer Institute, with 174 participants planned, started 2020-07-13 and due to reach its primary completion in 2024-10-24. Interventions recorded: Paclitaxel, Pertuzumab, Margetuximab, Trastuzumab. Conditions recorded: Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer.\n\nLinked to the drug Margetuximab because the registry names it among its interventions and Breast cancer and HER2-positive breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04425018","url":"https://clinicaltrials.gov/study/NCT04425018"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["paclitaxel","pertuzumab","margetuximab","trastuzumab","trastuzumab-biosimilars"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04425018","phase":"2","setting":"MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer","sponsor":"Dana-Farber Cancer Institute","enrolled":174,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04425018/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-biosimilars","kind":"drug","name":"Trastuzumab biosimilars","route":"/drugs/trastuzumab-biosimilars/"}]}}